Query String: DARUNAVIR
BDBM468559 US10806794, Compound mPEG3-N-Darunavir
BDBM468562 US10806794, Compound mPEG3-O-Darunavir
BDBM468563 US10806794, Compound mPEG5-O-Darunavir
BDBM468564 US10806794, Compound mPEG7-O-Darunavir
US10806794, Compound mPEG5-N-Darunavir BDBM468560
US10806794, Compound mPEG7-N-Darunavir BDBM468561
CHEMBL1323 Darunavir TMC-114 BDBM8125 US10806794, Compound Darunavir UIC-94017 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl N-[(2S,3R)-4-[(4-aminobenzene)(2-methylpropyl)sulfonamido]-3-hydroxy-1-phenylbutan-2-yl]carbamate Darunavir (DRV)
- Ghosh, AK; Dawson, ZL; Mitsuya, H Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV. Bioorg Med Chem 15: 7576-80 (2007)
- Kovalevsky, AY; Ghosh, AK; Weber, IT Solution kinetics measurements suggest HIV-1 protease has two binding sites for darunavir and amprenavir. J Med Chem 51: 6599-603 (2008)
- Ghosh, AK; Shahabi, D; Kipfmiller, M; Ghosh, AK; Johnson, M; Wang, YF; Agniswamy, J; Amano, M; Weber, IT; Mitsuya, H Evaluation of darunavir-derived HIV-1 protease inhibitors incorporating P2' amide-derivatives: Synthesis, biological evaluation and structural studies. Bioorg Med Chem Lett 83: (2023)
- Hidaka, K; Kimura, T; Sankaranarayanan, R; Wang, J; McDaniel, KF; Kempf, DJ; Kameoka, M; Adachi, M; Kuroki, R; Nguyen, JT; Hayashi, Y; Kiso, Y Identification of Highly Potent Human Immunodeficiency Virus Type-1 Protease Inhibitors against Lopinavir and Darunavir Resistant Viruses from Allophenylnorstatine-Based Peptidomimetics with P2 Tetrahydrofuranylglycine. J Med Chem 61: 5138-5153 (2018)